In 2013, it was estimated that there are 382 million cases of diabetes mellitus (DM) worldwide, including Type One and Type Two (Diabetes Mellitus: Diagnosis, classification, and pathophysiology, 2015). DM refers to a group of common metabolic autoimmune disorders that involve hyperglycemia, or an excess of glucose in the bloodstream. In all cases for Type One DM, and in some situations for Type Two, patients who are diagnosed must be insulin-dependent. Insulin is a hormone that is secreted by the beta cells of the pancreas; it promotes the cellular uptake of glucose into skeletal and cardiac muscles, as well as in adipose (connective fat) tissue. Insulin also decreases the physiologic production of glucose (mostly in the liver) and turns off destructive ketone production (Poisoning & drug overdose, 2015). This medication is essential for patients with Type One DM as it is
…show more content…
For example, oral pills have been used in the diabetes care market for patients with Type Two DM, but its tweaked use for patients with Type One DM has not been fully discovered yet. However, the inhaled insulin brand Exubera was approved by the FDA in late January of 2006 for treatment of adults with type 1 or type 2 diabetes (Inhaled insulin earns FDA approval, 2006). Hopefully these sorts of alternative treatments will gain efficiency and popularity as time passes. Mainstream insulin therapies that do not require frequent injection would make an enormous impact in regard to people who may have trouble giving/receiving injections. Many individuals contend that DM, both Type One and Type Two, does not have a concrete cure; instead, patients who have diabetes would receive care so advanced that there would be little to no lifestyle change after diagnosis. Technologies such as these non-injectable treatments are an integral step toward achieving this
For example, oral pills have been used in the diabetes care market for patients with Type Two DM, but its tweaked use for patients with Type One DM has not been fully discovered yet. However, the inhaled insulin brand Exubera was approved by the FDA in late January of 2006 for treatment of adults with type 1 or type 2 diabetes (Inhaled insulin earns FDA approval, 2006). Hopefully these sorts of alternative treatments will gain efficiency and popularity as time passes. Mainstream insulin therapies that do not require frequent injection would make an enormous impact in regard to people who may have trouble giving/receiving injections. Many individuals contend that DM, both Type One and Type Two, does not have a concrete cure; instead, patients who have diabetes would receive care so advanced that there would be little to no lifestyle change after diagnosis. Technologies such as these non-injectable treatments are an integral step toward achieving this